180 Life Sciences Corp. - Common Stock (ATNF)

Competitors to 180 Life Sciences Corp. - Common Stock (ATNF)

Cara Therapeutics, Inc. 

Cara Therapeutics is another competitor in the field of pain management, focusing specifically on developing novel Kappa opioid receptor agonists for treating pruritus and other conditions. This aligns closely with 180 Life Sciences' area of interest in chronic pain management. Cara's advanced clinical trial progress and established relationships with regulatory bodies give them an edge in credibility and market reach, positioning them as a leading competitor.

HempFusion Wellness Inc.

HempFusion is involved in the manufacture and sale of hemp-derived wellness products, including those targeting inflammation and pain relief. They facilitate competition with 180 Life Sciences by positioning themselves as a wellness product company having a more commercialized approach to hemp-based treatments. While 180 Life Sciences is focused primarily on clinical trials and regulatory approval for therapeutic claims, HempFusion's broader consumer market reach provides them with a competitive edge in immediate revenue generation.

Sorrento Therapeutics, Inc.

Sorrento Therapeutics and 180 Life Sciences both operate in the biopharmaceutical sector, focusing on innovative treatment options for various diseases, including chronic pain and inflammation. They compete in developing novel therapies utilizing unique approaches such as monoclonal antibodies and cell therapies. Sorrento has a broader pipeline and larger market presence, which may provide them a competitive advantage in attracting investment and completing clinical trials more rapidly.

Tetra Bio-Pharma Inc.

Tetra Bio-Pharma is a biopharmaceutical company that also works in the area of cannabinoid-based medicines for a range of therapeutic applications including pain management. Both 180 Life Sciences and Tetra aim to provide innovative solutions within the cannabinoid space, but Tetra has made significant strides in developing clinical evidence and product offerings. This established track record gives Tetra a competitive advantage in the marketplace, resulting in a somewhat more robust position.

Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals focuses on transdermal cannabinoid therapies, targeting similar market segments as 180 Life Sciences. Both companies are exploring cannabinoid-based treatments for chronic pain and neurodegenerative conditions. Zynerba's proprietary delivery method may offer an innovative advantage that could appeal to patients and healthcare providers looking for alternative delivery routes, potentially placing them ahead in terms of patient acceptance and commercial viability.